Dr. Reddy's Laboratories, Incorporated

Msn Laboratories Private Limited

Reddy's Laboratories Ltd.

Manne Satyanarayana Reddy

Srinivasan Thirumalai Rajan

Sajja Eswaraiah

Muppa Kishore Kumar

Maramreddy Sahadeva Reddy

Revu Satyanarayana

Chakilam Nagaraju

Koilkonda Purandhar

Keshaboina Sreenath

Thirumalai Rajan Srinivasan

Achampeta Kodanda Ramprasad

Mummadi Venkatesh

Venka Bhaskara Rao Uppala

Akundi Surya Prabhakar

Durgadas Shyla Prasad

Vijayavitthal Thippannachar Mathad

Kikkuru Srirami Reddy

Suraparaju Raghuram

Gudipati Srinivasulu

Mandava Venkata Naga Brahmeshwar Rao

Bojja Ramachandra Reddy

Pondichetty Anilkumar

Aluru Srinivas

Maram Reddy Sahadeva Reddy

Govindan Shanmugam

Vetukuri Venkata Naga Kali Vara Prasada Raju

Rapolu Rajesh Kumar

Ningam Srinivasreddy

Achampeta Kodanda Ram Prasad

Sunkara Vishnuvardhan

Vedantham Ravindra

Mathad Vijayavitthal Thippannachar

Singamsetty Radhakrishna

Karamala Rama Subba Reddy

Elati Ravi Ram Chandrashekar

Elati Ravi Rama Chandrashekar

Podichetty Anil Kumar

Kolla Naveen Kumar

Karamala Ramasubba Reddy

Mokkarala Suryanarayana Murthy

A process for the preparation of 4-[4-[4-[4-[[(3R,5R)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-[(1S,2S)-1-ethyl-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one compound of formula-1, its intermediates and polymorphs thereof. (I). 

Process for the preparation of triazole antifungal drug, its intermediates and polymorphs thereof

An dabigatran etexilate intermediate of Formula-6a, and the use in the preparation of dabigatran etexilate thereof.

Process for the preparation of benzimidazole derivatives and its salts

The present invention relates to an improved process for the preparation of amide intermediates useful in the preparation of cholesterol reducing agents.

Process for the preparation of amide intermediates and their use thereof

Processes for preparing and purifying (R)-2-acetamido-N-benzyl-3-methoxy-propionamide of formula-1 and intermediates thereof are provided. 

Process for preparing (R)-2-acetamido-N-benzyl-3-methoxy-propionamide

Processes for preparing pravastatin, intermediates and pharmaceutically acceptable salts thereof are provided Crystalline forms of pravastatin, intermediates and pharmaceutically acceptable salts thereof are also disclosed.

Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof

The present invention relates to a novel process for the preparation of paliperidone and its intermediates and also relates to an improved process for the preparation of paliperidone compound of formula (I). 

Processes for the preparation of paliperidone

Novel process for statins and its pharmaceutically acceptable salts thereof represented by general formula (I). 

Process for statins and its pharmaceutically acceptable salts thereof

The present invention relates to improved processes for the preparation of endolthelin receptor antagonists darusentan and ambrisentan, their salts and intermediates. Processes for the preparation of darusentan and ambrisentan comprise reacting benzophenone with a compound of Formula-3 to provide a compound of Formula-4, which on in-situ treatment with methanol and a suitable acid provides a compound of Formula-5; hydrolyzing the compound of Formula-5 to provide a compound of Formula-6; resolving the compound of Formula-6 to provide a compound of Formula-7; esterifying the compound of Formula-7 to provide a compound of Formula-8; reacting the compound of Formula-8 with a compound of Formula-9 to provide a compound of Formula-10; hydrolyzing the compound of Formula-10 to provide darusentan or ambrisentan; and purifiying darusentan or ambrisentan to provide darusentan or ambrisentan having purity greater than 99.00% by HPLC.

Process for the preparation of endothelin receptor antagonists

Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof represented by the general formula-(1) through novel intermediate compounds of general formula-(4). 

Process for the preparation of statins and their pharmaceutically acceptable salts thereof

A process for the preparation of pure Duloxetine hydrochloride comprises the steps of: a) reacting 1-(thiophen-2-yl)ethanone with dimethylamine hydrochloride, b) purifying the component in a solvent, c) reducing the component with an alkali metal borohydride, d) resolving the compound with a chiral acid, and treating the obtained compound with weak inorganic base, e) reacting the compound to give Duloxetine oxalate salt and f) converting the Duloxetine salt into its hydrochloride salt. Further the purifications of the obtained compound and of two intermediate products are described.

Process for pure duloxetine hydrochloride

An improved process for the preparation of Montelukast and its pharmaceutically acceptable salts comprises of reacting (S) Benzenepropanol &#x3b1;-[3-[2-(7-chloro2-quinolinyl)ethenyl]phenyl]-2-(1-hydroxy-1-methyl ethyl)-&#x3b1;-methane sulfonate compound of formula (II) with 1-(mercapto methyl)cyclo propane acetic acid or its ester or nitrile in presence of alkali or alkaline carbonates and/or alkali or alkaline earth metal alkoxide in a suitable polar aprotic solvent with or without combination of C-Calcoholic solvents and then treating with organic amine in a suitable ester and/or acetone and/or aliphatic or aromatic hydrocarbon solvents, and converting the corresponding amine salt compound of montelukast into its sodium salt compound of formula (I) using sodium ion source in methanol, without converting into montelukast free acid. 

Process for the preparation of Montelukast and its pharmaceutically acceptable salts

The present invention encompasses novel intermediates of pregabalin, namely 3-cyano-5-methyl hexanamide (28) and 3-(amino methyl)-5 methyl hexanamide (29), and processes for their preparation. The invention also encompasses a process for converting the novel pregabalin intermediates into pregabalin, Formula (I): The present invention further provides a cost effective method for the synthesis of (S)-pregabalin, which involves the recovery of mandelic acid and tartaric acid used in the resolution process and recycling them, increasing the yields of the final product formed, which substantially reduced the cost of the production. 

Process for the preparation of pregabalin

A hydrate of esomeprazole magnesium in the form of an amorphous solid is provided. Methods of preparation and use of, as well as formulation containing the hydrate of esomeprazole magnesium in the form of an amorphous solid are also provided.

Preparation of amorphous hydrous esomeprazole magnesium

The present invention provides an improved process for the preparation of highly pure montelukast sodium through highly pure diol intermediate compound of formula (2) and (1)-(mercapto methyl)cyclopropane acetic acid methyl ester compound of formula (4) or mercaptomethyl cyclopropane acetic acid compound of formula (7). The present invention also provides novel organic amine salts of montelukast. 

Process for pure montelukast sodium through pure intermediates as well as amine salts

The present invention relates to a cost effective and industrially advantageous process for the preparation of (3R,4S)-1-(4-fluorophenyl)-3-[3(S)-3-(4-fluorophenyl)-3-hydroxypropyl)]-4-(4-hydroxyphenyl)-2-azetidinone, referred to here as Ezetimibe and represented by structural formula (I). The process comprises an multi-step reaction sequence that includes a chiral auxiliary-controlled condensation, a silyl-mediated cyclization, a palladium-catalyzed Negishi cross-coupling, and the enantioselective reduction of a ketone to a hydroxyl group. 

Growing community of inventors

Hyderabad Telangana, India

Manne Satyanarayana Reddy